Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw.
OBJECTIVE
To investigate the effects of emodin on the treatment of non-alcoholic fatty liver in rats induced by high caloric laboratory chaw.


METHODS
Non-alcoholic fatty liver model was successfully established by feeding with high caloric laboratory chaw for 12 wk. Then the model rats were randomly divided into 3 groups, namely model control group, emodin group and dietary treatment group. The rats in emodin group were given emodin at dose of 40 mg/(kg x d) while animals in other groups were given distilled water of the same volume. The rats in model control group were fed with high caloric laboratory chaw while animals in other groups were fed with normal diet. Four weeks later, liver index (liver/body weight ratio), serum activities of liver-associated enzymes, blood lipid, fasting blood glucose, fasting plasma insulin, HOMA insulin resistance index (HOMA-IR), hepatic triglyceride content and histology features of all groups were assayed. The expression of hepatic peroxisomal proliferator activated receptor (PPAR) gamma was determined by RT-PCR.


RESULTS
The body weight, liver index, serum activities of alanine aminotransferase (ALT), blood lipid, hepatic triglyceride content of model control group were significantly elevated, with moderate to severe hepatocyte steatosis. The expression of hepatic PPAR gamma mRNA was obviously reduced in model control group. Compared with model control group, the body weight, liver index, serum activities of ALT, blood lipids and hepatic triglyceride of emodin group significantly decreased and hepatic histology display was also greatly improved. Meanwhile, the expression of hepatic PPAR gamma mRNA was elevated. However, high serum activities of ALT and hyperlipidemia were persisted in dietary treatment group although liver index was decreased and liver histology was somewhat improved.


CONCLUSIONS
It is suggested that emodin might be effective in the treatment of non-alcoholic fatty liver in rats. Its therapeutic mechanism could be associated with increasing the expression of hepatic PPAR gamma mRNA.
Dong
Hui
H
Institute of Integrative Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
Lu
Fu-Er
FE
Gao
Zhi-Qiang
ZQ
Xu
Li-Jun
LJ
Wang
Kai-Fu
KF
Zou
Xin
X
D000410:Alanine Transaminase / Q000378:metabolism; D000821:Animal Feed; D000818:Animals; D001219:Aspartate Aminotransferases / Q000378:metabolism; D001786:Blood Glucose; D001835:Body Weight; D004642:Emodin / Q000494:pharmacology*; D002149:Energy Intake; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005215:Fasting; D005234:Fatty Liver / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D009929:Organ Size; D047495:PPAR gamma / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D014280:Triglycerides / Q000378:metabolism
D001786:Blood Glucose; D004791:Enzyme Inhibitors; D008055:Lipids; D047495:PPAR gamma; D012333:RNA, Messenger; D014280:Triglycerides; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D004642:Emodin